ABSTRACT
Two ligand oligopeptides GV1 and GV2 were designed according to the putative binding region of VEGF to its receptors. GV1, GV2 and endosome releasing oligopeptide HA20 were conjugated with poly-L-lysine or protamine and the resulting conjugates could interact with DNA in a noncovalent bond to form a complex. Using pSV2-β-galactosidase as a reporter gene, it has been demonstrated that exogenous gene was transferred into bovine aortic arch-derived endothelial cells (ABAE) and human malignant melanoma cell lines (A375) in vitro. In vivo experiments, exogenous gene was transferred into tumor vascular endothelial cells and tumor cells of subcutaneously transplanted human colon cancer LOVO, human malignant melanoma A375 and human hepatoma graft in nude mice. This system could also target gene to intrahepatically transplanted human hepatoma injected via portal vein in nude mice. These results are correlated with the relevant receptors (flt-1, flk-1/KDR) expression on the targeted cells and tissues.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
George Y Wu, Catherine H Wu . Receptor-mediated in vitro gene transformation by a soluble DNA carrier system. J Biol Chem 1987; 262(10):4429–32.
Ernst Wagner, Martin Zenke, Matt Cotton et al. Transferrin-polycation conjugates as carriers for DNA uptake into cells. Proc Natl Acad Sci USA 1990; 87:3410–4.
Tian Peikun, Ren Shengjun, Ren Changchun et al. A Novel Receptor-targeted Gene Delivery System for cancer gene therapy, Science in China (Series C), accepted.
Ulla Wienhues, Keiichi Hosokawa . Arnd Hoveler etal. A novel method for transfection and expression of reconstituted DNA-protein complexes in eukaryotic cells, DNA. 1987; 6(1):81–9.
Judah Folkman, Yuen Shing . Angiogenesis. J Biol Chem 1992; 267(16):10931–34.
Napoleone Ferrara . Vascular endothelial growth factor. Trends Cardiovasc Med 1993; 3:244–50.
Erika Hatva, Arta Kaipainen, Panu Mentula et al. Expression of endothelial cell specific receptor tyrosine kinases and growth factors in human brain tumors, American Journal of Pathology. 1995; 146(2):368–78.
Kunio Suzuki, Norio Hayashi, Yasuhide Miyamoto et al. Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma, Cancer Res 1996; 56:3004–9.
Christine A Boocock, D Stepjen Charnock-Jones, Andrew M Sharkey et al. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Nat Cancer Inst 1995; 87:506–16.
Bo Liu, Helena M Earl, Dilair Baban et al. Melanoma cell lines express VEGF receptor KDR and respond to exogenously added VEGF. Biochem Biophy Res Commun 1995; 217(3):721–7.
Adrian L Harris, Huatang zhang, Amir Moghaddam et al. Breast cancer angiogenesis-new approaches to therapy via antigiogenesis, hypoxic activated drugs and vascular targeting, Breast Cancer Reasearch and Treament. 1996; 38:97–108.
Karl H Plate, Georg Breier, Herbert A Weich et al. Vascular endothelial growth factor is a potential tumour andiogenesis factor in human gliomas in vivo Nature, 1992; 359:845–8.
Mingli Sheng et al. Culture of Vascular Endothelial cell 1987; 14(1):71–3.
S. Ramakrishnan, TA Olson, VL Bautch et al. Vascular endothelial growth factor-toxin conjuate specifically inhibits KDR/flk-1 positive endothelial cell proliferation in vitro and angiogenesis in vivo. Cancer Res 1996; 56:1324–30.
Hela Gitary-Goren, Shay Soker, Israel Vlodavsky et al. The binding of vascular endothelial growth factor to its receptors is dependent on cell surface asssociated heparin-like molecules. J Biol Chem 1992; 267(9):6093–8.
G Neufeld, D Gospodarowicz . Protamine sulfate inhibits mitogenic activities of the extracellular matrix and fibroblast growth factor, but potentiates that of epidermal growth factor. J Cell Phys 1987; 132:287–94
Masayuki Murata, Satoshi Kagiwada, Sho Takahashi et al. Membrane Fusion induced by mutual interaction of the two charge-reversed amphiphilic peptides at neutral pH. J Biol Chem 1991; 266(22):14353–8.
Judah Folkman . What is the evidence that tumors are angiogenesis dependent J Nat Cancer Inst 1990; 88:4–6.
Acknowledgements
The present study has been granted by Biotechnology Project, National High Technology Program (Project No. Z-20-01-01). We thank Professor SHENG Minli and JIANG Yamei in Institute of Medical Radiology, Shanghai Medical University for their kind gift of ABAE cells.
Author information
Authors and Affiliations
Corresponding author
Additional information
The present receptor-mediated gene delivery system has been patented by Gu and Tian (Patent Registration number in China 96116557 X; PCT/CN 97/00106)
Rights and permissions
About this article
Cite this article
LI, J., HAN, J., HUANG, Y. et al. A novel gene delivery system targeting cells expressing VEGF receptors. Cell Res 9, 11–25 (1999). https://doi.org/10.1038/sj.cr.7290002
Issue date:
DOI: https://doi.org/10.1038/sj.cr.7290002
Keywords
This article is cited by
-
Progress in non-viral gene delivery systems fabricated via supramolecular assembly
Chinese Science Bulletin (2005)
-
Systemic genetic transfer of p21WAF−1 and GM-CSF utilizing of a novel oligopeptide-based EGF receptor targeting polyplex
Cancer Gene Therapy (2003)
-
Enhanced antitumor effect of EGF R–targeted p21WAF-1 and GM-CSF gene transfer in the established murine hepatoma by peritumoral injection
Cancer Gene Therapy (2002)
